论文部分内容阅读
目的:观察贞芪扶正胶囊与乙肝疫苗联用(EV治疗)对HBV不同复制水平的影响。方法:中～高水平复制者19例(A组)及低水平复制者26例(B组)给予EV治疗,另外低水平复制者19例(C组)作空白对照。以PCR及ELISA定量检测评价疗效。结果:A组5.26％病毒复制终止,HBsAg明显下降(P<0.01),35.71％HBeAg转阴。B组73.07％病毒复制终止,HBsAg下降非常显著(P<0.01),87.50％HBeAg转阴。C组5.26％病毒复制终止,而HBeAN、HBV-DNA阳性率有所升高,但统计学差异不明显(P>0.05)。组间比较B组明显优于A组和c组(P<0.01)。结论:EV治疗能抑制HBV的复制与表达,可使73.07％的低水平复制者近期获愈。
Objective: To observe the effect of Zhenqi Fuzheng Capsule combined with Hepatitis B Vaccine (EV treatment) on different HBV replication levels. Methods: Nineteen patients with moderate to high level of replication (group A) and 26 patients with low level of replication (group B) were treated with EV, and 19 patients with low level of replication (group C) as blank control. PCR and ELISA quantitative detection to evaluate the efficacy. Results: In group A, 5.26% viral replication was terminated, HBsAg was significantly decreased (P <0.01), and 35.71% of HBeAg was negative. In group B, 73.07% viral replication was terminated, HBsAg decreased significantly (P <0.01), and 87.50% HBeAg was negative. In group C, 5.26% of viral replication was terminated, while the positive rate of HBeAN and HBV-DNA was increased, but the difference was not statistically significant (P> 0.05). Group B was significantly better than group A and group c (P <0.01). Conclusion: EV treatment can inhibit the replication and expression of HBV, which can make 73.07% of low-level replicators recover more recently.